Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederir.kuraoncology.com
Kura Oncology, Inc. News Releases
Get the latest updates from Kura Oncology, Inc. News Releases directly as they happen.
Follow now 40 followers
Latest posts
Last updated about 10 hours ago
Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress
about 10 hours ago
– Ziftomenib combined with 7+3 in 1L NPM1 -m or KMT2A -r...
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
9 days ago
SAN DIEGO , May 06, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc...
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13 days ago
SAN DIEGO , May 02, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc...
Kura Oncology Reports First Quarter 2025 Financial Results
13 days ago
– NDA submitted in 1Q 2025 for ziftomenib for the treatment of...
Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST
17 days ago
– Phase 1 dose-escalation study to evaluate ziftomenib in combination with imatinib...
Kura Oncology to Report First Quarter 2025 Financial Results
21 days ago
SAN DIEGO , April 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc...
Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA
about 1 month ago
– Submission seeks approval for the treatment of adult patients with relapsed...
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
about 1 month ago
SAN DIEGO , April 04, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc...
Kura Oncology to Participate in Stifel Targeted Oncology Forum
about 1 month ago
SAN DIEGO , April 01, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc...
Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting
about 2 months ago
– Oral presentation to highlight preclinical data further supporting combination of KO-2806...
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2 months ago
SAN DIEGO , March 07, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc...
Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results
3 months ago
– KOMET-001 registrational trial in R/R NPM1 -mutant AML achieved primary endpoint...